中樞神經系統的共同研究·授權契約(2020年～2025年)

本報告提供全球生物醫藥品產業調查分析，提供2020年～2025年的中樞神經系統的共同研究·授權契約811件相關，契約條件等詳細資訊。

目錄

摘要整理

第1章 簡介

第2章 中樞神經系統契約趨勢

• 簡介
• 過去數年的中樞神經系統合作夥伴契約
• 中樞神經系統合作夥伴契約:各類型契約
• 中樞神經系統合作夥伴契約:各產品部門
• 中樞神經系統合作夥伴契約:各開發階段
• 中樞神經系統合作夥伴契約:各技術類型
• 中樞神經系統合作夥伴契約:各適應症

第3章 中樞神經系統合作夥伴契約相關財務的契約條件

• 簡介
• 中樞神經系統合作夥伴契約相關公開的財務條件
• 中樞神經系統合作夥伴契約的標題金額
• 中樞神經系統契約的預付款
• 中樞神經系統契約的階段性付款
• 中樞神經系統的權利金費率

第4章 主要中樞神經系統契約與談判者

• 簡介
• 在中樞神經系統合作夥伴契約領域中最活躍
• 中樞神經系統領域的最活躍的談判者的清單
• 前幾名的中樞神經系統契約(金額)

第5章 中樞神經系統契約文件名錄

• 簡介
• 合同可取得的中樞神經系統合作夥伴契約

第6章 中樞神經系統契約:治療標的

• 簡介
• 契約:中樞神經系統治療標的
• 契約名錄
• 契約名錄 - 中樞神經系統契約:各企業(A～Z)(2020年～2025年)
• 契約名錄 - 中樞神經系統契約:各技術類型(2020年～2025年)
• 契約類型定義
• 關於Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Current Partnering的近幾年報告的標題

Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 811 central nervous system deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in central nervous system dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the central nervous system field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in central nervous system dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of central nervous system deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of central nervous system deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse central nervous system collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Central Nervous System Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of central nervous system trends and structure of deals entered into by leading biopharma companies worldwide.

Central Nervous System Collaboration and Licensing Deals includes:

• Trends in central nervous system dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of central nervous system deal records covering pharmaceutical and biotechnology
• The leading central nervous system deals by value
• Most active central nervous system licensing dealmakers

In Central Nervous System Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Central Nervous System Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

• 2.1. Introduction
• 2.2. Central nervous system partnering over the years
• 2.3. Central nervous system partnering by deal type
• 2.4. Central nervous system partnering by industry sector
• 2.5. Central nervous system partnering by stage of development
• 2.6. Central nervous system partnering by technology type
• 2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for central nervous system partnering
• 3.3. Central nervous system partnering headline values
• 3.4. Central nervous system deal upfront payments
• 3.5. Central nervous system deal milestone payments
• 3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in central nervous system partnering
• 4.3. List of most active dealmakers in central nervous system
• 4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory

• 5.1. Introduction
• 5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by central nervous system therapeutic target
• Deal Directory
• Deal Directory - Central nervous system deals by company A-Z 2020 to 2025
• Deal Directory - Central nervous system deals by technology type 2020 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Central nervous system partnering since 2020
• Figure 2: Central nervous system partnering by deal type since 2020
• Figure 3: Central nervous system partnering by industry sector since 2020
• Figure 4: Central nervous system partnering by stage of development since 2020
• Figure 5: Central nervous system partnering by technology type since 2020
• Figure 6: Central nervous system partnering by indication since 2020
• Figure 7: Central nervous system deals with a headline value
• Figure 8: Central nervous system deals with upfront payment values
• Figure 9: Central nervous system deals with milestone payment
• Figure 10: Central nervous system deals with royalty rates
• Figure 11: Active central nervous system dealmaking activity since 2020
• Figure 12: Top central nervous system deals by value since 2020